Relmada Therapeutics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
RLMD
- Investments
-
3
- Share Price
-
$4.16
- (As of Thursday Closing)
Relmada Therapeutics General Information
Description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Contact Information
Website
www.relmada.comCorporate Office
- 2222 Ponce de Leon Boulevard
- Floor 3
- Coral Gables, FL 33134
- United States
Corporate Office
- 2222 Ponce de Leon Boulevard
- Floor 3
- Coral Gables, FL 33134
- United States
Relmada Therapeutics Stock Performance
As of 12-Nov-2026, Relmada Therapeutics’s stock price is $4.16. Its current market cap is $444M with 107M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.16 | $4.43 | $3.07 - $8.00 | $444M | 107M | 1.35M | -$0.91 |
Relmada Therapeutics Financials Summary
As of 30-Jun-2026, Relmada Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 492,549 | 340,315 | (38,427) | 18,344 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (65,821) | (58,781) | (83,509) | (103,943) |
| Net Income | (61,925) | (57,385) | (79,979) | (98,792) |
| Total Assets | 219,059 | 94,003 | 45,818 | 97,552 |
| Total Debt | 0 | 0 | 0 | 0 |
Relmada Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Relmada Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Relmada Therapeutics Comparisons
Industry
Financing
Details
Relmada Therapeutics Competitors (57)
One of Relmada Therapeutics’s 57 competitors is IRulya Therapeutics, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IRulya Therapeutics | Formerly VC-backed | New Haven, CT | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Geron | Formerly VC-backed | Foster City, CA | ||||
| aTyr Pharma | Formerly VC-backed | San Diego, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Relmada Therapeutics Patents
Relmada Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220105085-A1 | Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist | Inactive | 31-Jan-2019 | ||
| WO-2020159901-A1 | Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist | Inactive | 31-Jan-2019 | ||
| EP-3579843-B1 | 3-beta-hydroxy-5-alpha-pregnan-20-one for the treatment of tourette's syndrome, obsessive compulsive disorder and/or gambling disorder | Active | 10-Feb-2017 | ||
| ES-3058488-T3 | 3-beta-hydroxy-5-alpha-pregnan-20-one for the treatment of tourette's syndrome, obsessive compulsive disorder and/or gambling disorder | Active | 10-Feb-2017 | ||
| AU-2018218823-A1 | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment | Active | 10-Feb-2017 | A61K31/573 |
Relmada Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Relmada Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Relmada Therapeutics Investments & Acquisitions (3)
Relmada Therapeutics’s most recent deal was a Corporate Asset Purchase with Asarina Pharma (Tourette Syndrome Therapy Compound Rights) for . The deal was made on 06-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Asarina Pharma (Tourette Syndrome Therapy Compound Rights) | 06-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Camp Nine | 10-Jun-2014 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Medeor | 01-Dec-2013 | Merger/Acquisition | Other Healthcare Services |
Relmada Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.96 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Relmada Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Medeor | Tonisvorst, Germany | 1964 |
Relmada Therapeutics FAQs
-
When was Relmada Therapeutics founded?
Relmada Therapeutics was founded in 2004.
-
Where is Relmada Therapeutics headquartered?
Relmada Therapeutics is headquartered in Coral Gables, FL.
-
What is the size of Relmada Therapeutics?
Relmada Therapeutics has 17 total employees.
-
What industry is Relmada Therapeutics in?
Relmada Therapeutics’s primary industry is Drug Discovery.
-
Is Relmada Therapeutics a private or public company?
Relmada Therapeutics is a Public company.
-
What is Relmada Therapeutics’s stock symbol?
The ticker symbol for Relmada Therapeutics is RLMD.
-
What is the current stock price of Relmada Therapeutics?
As of 12-Nov-2026 the stock price of Relmada Therapeutics is $4.16.
-
What is the current market cap of Relmada Therapeutics?
The current market capitalization of Relmada Therapeutics is $444M.
-
Who are Relmada Therapeutics’s competitors?
IRulya Therapeutics, Minerva Neurosciences, Geron, aTyr Pharma, and Sarepta Therapeutics are some of the 57 competitors of Relmada Therapeutics.
-
What is Relmada Therapeutics’s annual earnings per share (EPS)?
Relmada Therapeutics’s EPS for 12 months was -$0.91.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
